SLC5A2 and depressive symptom measurement: After exclusion of those with previous psychiatric disorders, 72 420 users of GLP-1 receptor agonists and 111 083 users of SGLT2 inhibitors were included in the analysis of incident depression and anxiety-related disorders (patient characteristics are summarized in eTable 7 in Supplement 1).